PROGRAM SNAPSHOT

Aspect Biosystems — Bioprinted Islet Tissue

🔬 Emerging Contender Company-Reported

A bioprinted islet-tissue program that just changed hands — same underlying science, new operator.

What's actually shown: Novo Nordisk exited cell-therapy development entirely in October 2025 and transferred its stem-cell-derived islet/hypoimmune tech to Aspect Biosystems, which now leads the program from its own sites. Novo keeps a financial stake (investment, royalties, an option to expand involvement later) but is no longer the operating partner. The underlying science and data are unchanged.

Provisional score. This score is held provisional rather than recalculated, pending confirmation of execution continuity under Aspect's lead — worth a fresh look before this program anchors a post.

Last verified: 2026-08-24. Sources: FierceBiotech on the Novo/Aspect restructuring.

This is a Program Snapshot, not yet a full Trial Report Card — a full Report Card means the deeper eligibility, risk, and enrollment research we do for each Cure Radar post. Follow @t1dcureintelligence for the full breakdown when this program gets its own deep-dive.

← Back to the full leaderboard